Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Fig. 5

Dapagliflozin improved apoptosis, pathological injuries and cholesterol accumulation in glomerulus of DN. (A) WB revealed that dapagliflozin treatment could relieve apoptosis which were induced in DN group. (B) Dapagliflozin could restore the expression of podocin and nephrin compared with DN group. (C) HE, PAS and MASSON staining showed dapagliflozin could alleviate pathological injuries compared with DN group. (D) IF showed dapagliflozin treatment could restore the expression of podocin. (E) Cholesterol detected in serum showed that dapagliflozin could significantly reduce the content when compared with DN group. (Data are the mean ± S.D.; *P < 0.05 vs. CTR, # P < 0.05 vs. DN, n = 3)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us